{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:14:25Z","timestamp":1777932865240,"version":"3.51.4"},"reference-count":35,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Rejuvenation Research"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:p>\n                    Stem cell research and related therapies (including regenerative medicine and cellular therapies) could have a significant near-term impact on worldwide public health and aging. One reason is the industry's strong linkage between policy, science, industry, and patient advocacy, as was clear in the attendance and programming at the 7\n                    <jats:sup>th<\/jats:sup>\n                    annual World Stem Cell Summit held in Pasadena, California, October 3\u20135, 2011. A special conference session sponsored by the SENS Foundation discussed how stem cell therapies are being used to extend healthy life span. Stem cells are useful not only in cell-replacement therapies, but also in disease modeling, drug discovery, and drug toxicity screening. Stem cell therapies are currently being applied to over 50 diseases, including heart, lung, neurodegenerative, and eye disease, cancer, and human immunodeficiency virus (HIV)\/acquired immunodeficiency syndrome (AIDS). Dozens of companies are developing therapeutic solutions that are in different stages of clinical use and clinical trials. Some high-profile therapies include Dendreon's Provenge for prostate cancer, Geron's first-ever embryonic stem cell trials for spinal cord injury, Fibrocell's laViv cellular therapy for wrinkles, and well-established commercial skin substitutes (Organogenesis' Apligraf and Advanced BioHealing's Dermagraft). Stem cell policy issues under consideration include medical tourism, standards for large-scale stem cell manufacturing, and lingering ethical debates over the use of embryonic stem cells. Contemporary stem cell science advances include a focus on techniques for the direct reprogramming of cells from one lineage to another without returning to pluripotency as an intermediary step, improved means of generating and characterizing induced pluripotent cells, and progress in approaches to neurodegenerative disease.\n                  <\/jats:p>","DOI":"10.1089\/rej.2011.1292","type":"journal-article","created":{"date-parts":[[2011,12,16]],"date-time":"2011-12-16T15:57:41Z","timestamp":1324051061000},"page":"699-704","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Steady Advance of Stem Cell Therapies: Report from the 2011 World Stem Cell Summit, Pasadena, California, October 3\u20135"],"prefix":"10.1177","volume":"14","author":[{"given":"Melanie","family":"Swan","sequence":"first","affiliation":[{"name":"MS Futures Group"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Hsu J. Fear of risk threatens medical innovation. Innovation News Daily. June 29 2011. www.innovationnewsdaily.com\/medical-innovation-pharmaceutical-drugs-2090\/. 2011 October 9."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2009.07.002"},{"key":"e_1_3_1_4_2","unstructured":"Sharma A. Cell Cure partner Teva to develop OpRegen. Pharma Age October 11 2010. www.pharmaage.com\/2010\/10\/11\/cell-cure-partner-teva-to-develop-opregen\/. 2011 October 9."},{"key":"e_1_3_1_5_2","unstructured":"Segall J. Company plans near-term commercialization of iPS cell banking services that reverse the developmental aging of human cells. Company press release January 3 2011. www.b2i.us\/profiles\/investor\/ResLibraryView.asp?ResLibraryID=42754&GoTopage=1&Category=1802&BzID=1152\/. 2011 October 9."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.2217\/rme.10.51"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/stem.499"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/scrt73"},{"key":"e_1_3_1_9_2","unstructured":"McKechnie C. GE Healthcare launches human cardiomyocytes for predictive toxicity testing. Company press release October 4 2010. www.genewscenter.com\/content\/detailEmail.aspx?NewsAreaID=2&ReleaseID=11106&AddPreview=False and http:\/\/www.gelifesciences.com\/aptrix\/upp01077.nsf\/content\/drug-safety-screening\/. 2011 October 9."},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2010.01.014"},{"key":"e_1_3_1_11_2","unstructured":"BabyCenter Medical Advisory Board. Fertility treatment: In vitro fertilization (IVF) Online text from BabyCenter 2011. www.babycenter.com\/0_fertility-treatment-in-vitro-fertilization-ivf_4094.bc\/. 2011 October 9."},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.2217\/rme.10.55"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-720X.2010.00488.x"},{"key":"e_1_3_1_14_2","unstructured":"Childs D. Peyton Manning's stem cell hail Mary. ABC News September 12 2011. http:\/\/abcnews.go.com\/blogs\/health\/2011\/09\/19\/peyton-mannings-stem-cell-hail-mary\/. 2011 October 9."},{"key":"e_1_3_1_15_2","unstructured":"Brown E. Rick Perry's stem cell surgery worries some doctors. Los Angeles Times August 19 2011. http:\/\/articles.latimes.com\/2011\/aug\/19\/news\/la-heb-rick-perry-stem-cell-back-surgery-20110819\/. 2011 October 9."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1353\/ken.2010.0001"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1582-8"},{"key":"e_1_3_1_18_2","unstructured":"U.S. National Institutes of Health. Stem Cell Basics. Stem Cell Information. http:\/\/stemcells.nih.gov\/info\/basics\/basics4.asp\/. 2011 October 9."},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.024"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.07.002"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09017"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09805"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2011.28"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1927"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/gm265"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2011.06.026"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813339106"},{"key":"e_1_3_1_28_2","unstructured":"Neuralstem Inc. Dr. Eva Feldman Principal Investigator presents interim data on Neuralstem ALS trial. Company press release. September 27 2011. http:\/\/investor.neuralstem.com\/phoenix.zhtml?c=203908&p=irol-newsArticle&ID=1610372&highlight=\/. 2011 October 9."},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.2741\/3528"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2011.06.008"},{"key":"e_1_3_1_31_2","unstructured":"Burgess S. FDA approves a cellular immunotherapy for men with advanced prostate cancer. U.S. Food and Drug Administration press release. April 29 2010. www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm210174.htm\/. 2011 October 9."},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0811-674"},{"key":"e_1_3_1_33_2","unstructured":"Geron Corporation. Geron presents data from GRNOPC1 trial at international conferences on spinal cord medicine and rehabilitation. Company press release June 7 2011. www.geron.com\/media\/pressview.aspx?id=1271\/. 2011 October 10."},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0311-05.2005"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802905"},{"key":"e_1_3_1_36_2","unstructured":"Barre-Sinoussi F. Toward an H.I.V. cure. New York Times June 3 2011. www.nytimes.com\/2011\/06\/04\/opinion\/04iht-edsinoussi04.html\/. 2011 October 9."}],"container-title":["Rejuvenation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/rej.2011.1292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/rej.2011.1292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/rej.2011.1292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T01:31:17Z","timestamp":1777685477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/rej.2011.1292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1089\/rej.2011.1292"],"URL":"https:\/\/doi.org\/10.1089\/rej.2011.1292","relation":{},"ISSN":["1549-1684","1557-8577"],"issn-type":[{"value":"1549-1684","type":"print"},{"value":"1557-8577","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}